Paul Tudor Jones’s Summit Therapeutics SMMT Stock Holding History

Paul Tudor Jones’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	+16,900	New	+$300K	﹤0.01%	3225
2025 Q2	–	Sell	-11,800	Closed	-$228K	–	3707
2025 Q1	$228K	Buy	11,800 +600	+5%	+$12K	﹤0.01%	2781
2024 Q4	$200K	Sell	11,200 -9,300	-45%	-$180K	﹤0.01%	2852
2024 Q3	$449K	Buy	+20,500	New	+$287K	﹤0.01%	2092

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Paul Tudor Jones's SMMT Position: Q2 2026 in Review

Paul Tudor Jones sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 384,988 shares — an estimated $6.83M sold.

Paul Tudor Jones first reported a position in SMMT in Q1 2023 and held it in 5 quarters. The position peaked at $7.4M in Q4 2025. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Paul Tudor Jones reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 384,988 Summit Therapeutics shares in Q2 2026, an estimated $6.83M.
Paul Tudor Jones first reported a position in Summit Therapeutics in Q1 2023 and held it in 5 quarters.
Paul Tudor Jones's Summit Therapeutics position peaked at $7.4M in Q4 2025.
241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.